Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
The First Nasal Treatment for Anaphylaxis: FDA APPROVED!
Mohamad-Ali Salloum, PharmD • August 17, 2024
Share
Anaphylaxis is a severe, life-threatening allergic reaction that can occur rapidly, requiring immediate medical intervention. Traditionally, epinephrine autoinjectors have been the standard of care for such emergencies. However, the recent approval by the U.S. Food and Drug Administration (FDA) of a novel nasal spray, named neffy, marks a significant milestone in the management of anaphylactic reactions
What is Neffy?
Neffy (epinephrine nasal spray) is the first of its kind for the emergency treatment of allergic reactions (Type I), including anaphylaxis, in adult and pediatric patients who weigh at least 30 kilograms (approximately 66 pounds). This approval is particularly noteworthy as it introduces the first non-injectable form of epinephrine, potentially reducing barriers to rapid treatment due to needle phobia
Why Neffy was approved?
The approval of Neffy was based on four studies involving 175 healthy adults, which demonstrated that the epinephrine concentrations in the blood following administration of Neffy were comparable to those achieved with approved epinephrine injection products. Additionally, Neffy showed similar increases in blood pressure and heart rate, which are critical effects of epinephrine in treating anaphylaxis.
How is it Administered?
Neffy is administered as a single dose nasal spray into one nostril and may be given a second dose if symptoms do not improve or worsen. It is important to note that certain nasal conditions, such as nasal polyps or a history of nasal surgery, may affect the absorption of Neffy. In such cases, patients are advised to consult with healthcare professionals regarding the use of injectable epinephrine products
Conclusion:
The introduction of neffy is a welcome addition to the arsenal of anaphylaxis treatments, offering a needle-free alternative that may encourage more timely administration of life-saving epinephrine. As with any new medical product, ongoing monitoring and real-world data will be essential to assess the long-term efficacy and safety of this innovative treatment option.
References :
-FDA Approves First Nasal Spray for Treatment of Anaphylaxis.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References: Harkin B, Webb TL, Chang BPI, Prestwich A, Conner M, Kellar I, et al. Does monitoring goal progress promote goal attainment? A meta-analysis of the experimental evidence. Psychol Bull . 2016;142(2):198–229. Available from: https://www.apa.org/pubs/journals/releases/bul-bul0000025.pdf Compernolle S, DeSmet A, Poppe L, Crombez G, De Bourdeaudhuij I, Cardon G, et al. Effectiveness of interventions using self-monitoring to reduce sedentary behavior in adults: a systematic review and meta-analysis. Int J Behav Nutr Phys Act . 2019;16(1):63. Available from: https://link.springer.com/article/10.1186/s12966-019-0824-3 Patel ML, Brooks TL, Bennett GG. Consistent self‑monitoring in a commercial app‑based intervention for weight loss: results from a randomized trial. J Behav Med . 2020;43:391–401. Available from: https://link.springer.com/article/10.1007/s10865-019-00091-8 Patel ML, Hopkins CM, Brooks TL, Bennett GG. Comparing self-monitoring strategies for weight loss in a smartphone app: randomized controlled trial. JMIR Mhealth Uhealth . 2019;7(2):e12209. Available from: https://mhealth.jmir.org/2019/2/e12209/ Lally P, Van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. Available from: https://repositorio.ispa.pt/bitstream/10400.12/3364/1/IJSP_998-1009.pdf Singh B, Murphy A, Maher C, Smith AE. Time to form a habit: A systematic review and meta-analysis of health behaviour habit formation and its determinants. Healthcare (Basel) . 2024;12(23):2488. Available from: https://www.mdpi.com/2227-9032/12/23/2488 Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: A meta‑analysis of effects and processes. In: Advances in Experimental Social Psychology . 2006;38:69–119. Available from: https://www.researchgate.net/publication/37367696 Adriaanse MA, Gollwitzer PM, De Ridder DTD, De Wit JBF, Kroese FM. Breaking habits with implementation intentions: A test of underlying processes. Pers Soc Psychol Bull . 2011;37(4):502–13. Available from: https://dspace.library.uu.nl/bitstream/handle/1874/380229/0146167211399102.pdf Palmer CA, Bower JL, Cho KW, Clementi MA, Lau S, Oosterhoff B, et al. Sleep loss and emotion: A systematic review and meta-analysis of over 50 years of experimental research. Psychol Bull . 2023;149(11):2314–48. Available from: https://www.apa.org/pubs/journals/releases/bul-bul0000410.pdf Kong Y, Yu B, Guan G, Wang Y, He H. Effects of sleep deprivation on sports performance and perceived exertion in athletes and non-athletes: a systematic review and meta-analysis. Front Physiol . 2025;16:1544286. Available from: https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1544286/full Tadros M, Newby JM, Li S, Werner‑Seidler A. Psychological treatments to improve sleep quality in university students: systematic review and meta-analysis. PLoS One . 2025;20(2):e0317125. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317125 Locke EA, Latham GP. Building a practically useful theory of goal setting and task motivation: A 35‑year odyssey. Am Psychol . 2002;57(9):705–17. Available from: https://med.stanford.edu/content/dam/sm/s-spire/documents/PD.locke-and-latham-retrospective_Paper.pdf
Reference: ACRP. “ICH E6(R2) to ICH E6(R3) Comparison.” (Jan 28, 2025) — terminology & essential records: PDF Clinical Trials Toolkit. “Summary of Key Changes in ICH E6(R3).” (Mar 25, 2025) — proportionality, QbD, safety reporting: Article PharmaEduCenter. “Key changes between ICH GCP E6 R3 and E6 R2.” (Aug 10, 2025) — structure & glossary: Blog CITI Program. “Navigating the Transition from ICH E6(R2) to ICH E6(R3).” (Mar 12, 2025) — consent & site practices: Blog IntuitionLabs. “ICH E6 (R3) Explained.” (Updated Jan 13, 2026) — rationale, data governance: Deep dive
Simplify your day with essentialism: set priorities, eliminate the non‑essential, time‑block deep work, and measure progress for stress‑free productivity.
A runner’s guide to VO₂ max: why plateaus happen and how to fix them with long intervals, tempo, hills, cross‑training and smart periodization.
Explore the science of cognitive dissonance and learn how attitude change occurs, why dissonance matters, and what recent brain studies reveal about decision-making and self-control.
Discover the science behind willpower and impulse control. Explore Dr. David Lewis’s “zombie brain” model, the ego depletion controversy, glucose myths, and evidence-based strategies like the 3-second pause, mindfulness, and environmental design to build lasting self-control.
Explore evidence-based insights into ACE inhibitors, calcium channel blockers, and ARBs for hypertension management.
Discover the latest scientific evidence (2022–2025) on Branched-Chain Amino Acids (BCAAs)—their role in muscle recovery, performance enhancement, and safety.
Explore the benefits of Combination therapy for patients with Hypertension.